Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours

British Journal of Cancer

Volumn 105, Issue 2, 2011, Pages 246-254

  Weidlich, S ^a   Walsh, K ^b   Crowther, D ^b   Burczynski, M E ^b   Feuerstein, G ^b   Carey, F A ^a   Steele, R J C ^a   Wolf, C R ^a   Miele, G ^b,c   Smith, G ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b HOFFMANN LA ROCHE INC   (United States)

^c Epistem Ltd   (United Kingdom)

Author keywords

colorectal tumour; dideoxy sequencing; K Ras; mutation; personalised medicine; pyrosequencing

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ACCURACY; ADULT; AGED; ARTICLE; CANCER GROWTH; COLORECTAL TUMOR; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE K RAS; PATHOGENESIS; PATHOLOGY; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; PYROSEQUENCING; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALITY; MALE; MIDDLE AGED; MUTATION; ONCOGENES; SEQUENCE ANALYSIS, DNA;

EID: 79960231716     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.197     Document Type: Article

References (58)

1. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634
3. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684 (Pubitemid 28222141)
4. Andreyev HJN, Norman AR, Cunningham D, Oates JR (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85: 692-696 (Pubitemid 32929467)
5. Bader AG, Kang S, Zhao L, Vogt PK (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929 (Pubitemid 41766781)
6. Baldus SE, Schaefer K-L, Engers R, Hartleb D, Stoecklein NH, Gabbert HE (2010) Prevalence and heterogeneity of KRas, BRaf, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastasis. Clin Cancer Res 16: 790-799
7. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671
8. Bollag G, Adler F, elMasry N, McCabe PC, Conner Jr E, Thompson P, McCormick F, Shannon K (1996) Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. J Biol Chem 271: 32491-32494 (Pubitemid 27008660)
9. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689 (Pubitemid 19213607)
10. Calistri D, Rengucci C, Seymour I, Lattuneddo A (2005) Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Phys 204: 484-488 (Pubitemid 40934643)
11. Cespedes MV, Sancho FJ, Guerrero S, Parreno M, Casanova I, Pavon MA, Marcuello E, Trias M, Cascante M, Capella G, Mangues R (2006) K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis 27: 2190-2200 (Pubitemid 44644807)
12. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ (2005) The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54: 1283-1286 (Pubitemid 41192491)
13. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345 (Pubitemid 38944402)
14. Davies H, Bignell GR, Cox C, Stephens P, Edkins S (2002) Mutations in the BRaf gene in human cancer. Nature 417: 949-952
15. de Castro-Carpeno J, Belda-Iniesta C, Casado Saenz E, Hernandez Agudo E, Feliu Batlle J, Gonzalez Baron M (2008) EGFR and colon cancer: a clinical view. Clin Transl Oncol 10: 6-13
16. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762
17. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304: 1812-1820
18. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515 (Pubitemid 351325672)
19. Des Guetz G, Uzzan B, Morere JF, Perret G, Nicolas P (2010) Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. Cochrane Database Systematic Review, (1): Article number: CD007046
20. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169 (Pubitemid 46625066)
21. Dufort S, Richard MJ, de Fraipont F (2009) Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 391: 166-168
22. Dukes CE (1932) The classification of cancer of the rectum. J Pathol Bacteriol 35: 323-332
23. Eng C (2009) Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 6: 207-218
24. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumori-genesis. Cell 61: 759-767
25. Greene FL (ed) (2002) AJCC Cancer Staging Manual. Springer: New York
26. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R (2000) K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60: 6750-6756
27. Guerrero S, Figueras A, Casanova I, Farre L, Lloveras B, Capella G, Trias M, Mangues R (2002) Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. FASEB J 16: 1642-1644
28. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ (2007) Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110: 980-988 (Pubitemid 47312862)
29. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765
30. Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M (2007) PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121: 1771-1778 (Pubitemid 47417296)
31. Koopman M, Punt CJ (2009) Chemotherapy, which drugs and when. Eur J Cancer 45(Suppl 1): 50-56
32. Leslie A, Pratt NR, Gillespie K, Sales M, Kernohan NM (2003) Mutations in APC, K-Ras and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinoma. Cancer Res 63: 4656-4661 (Pubitemid 36951044)
33. Lievre A, Bachet J-B, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379 (Pubitemid 351171687)
34. Lièvre A, Bachet J-B, Corre DL, Boige V, Landi B, Emile J-F, Cote J-F, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Lorca F, Laurent-Puig P (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995
35. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338 (Pubitemid 37328853)
36. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279 (Pubitemid 44301348)
37. Nicolantonio FD, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, Dosso SD, Maxxucchelli L, Frattini M, Siena S, Bardelli A (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712
38. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10: 534-541 (Pubitemid 351770297)
39. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS (2005) Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7: 413-421 (Pubitemid 41149657)
40. Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, Capelinha AF, Duval A, Hamelin R, Machado JC, Schwartz Jr S, Carneiro F, Seruca R (2007) KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26: 158-163 (Pubitemid 46067341)
41. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S (2009) PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15: 3184-3188
42. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208 (Pubitemid 41079832)
43. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554 (Pubitemid 38541907)
44. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851-1857
45. Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272 (Pubitemid 44497237)
46. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130: 247-253
47. Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR (2010) Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours-implications for personalised cancer medicine. Br J Cancer 102: 693-703
48. Smith G, Carey FA, Beattie J, Wilkie MJV, Lightfood TJ (2002) Mutations in APC, Kirsten-Ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 99: 9433-9438 (Pubitemid 34764631)
49. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR (2000) Prognostic significance of TP53 gene mutations in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 36: 2053-2060
50. Söreide K, Janssen EAM, Söiland H, Körner H, Baak JPA (2006) Microsatellite instability in colorectal cancer. Br J Surg 93: 395-406
51. Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR, Chan YW, Chan AS, Chan TL, Wu TT, Rashid A, Hamanaka Y, Hinoda Y, Shannon RL, Wang X, Morris J, Issa JP, Yuen ST, Leung SY, Hamilton SR (2008) Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res 14: 2560-2569
52. Tsukuda K, Tanino M, Soga H, Shimizu N, Shimizu K (2000) A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun 278: 653-658
53. van Krieken H, Tol J (2009) Setting future standards for KRAS testing in colorectal cancer. Pharmacogenomics 10: 1-3
54. Van Meter ME, Kim ES (2010) Bevacizumab: current updates in treatment. Curr Opin Oncol 22: 586-591
55. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G (2005) The prevalence of PI3KCA mutations in gastric and colon cancer. Eur J Cancer 41: 1649-1654 (Pubitemid 40981849)
56. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC (1988) Genetic alterations during colorectal tumour development. N Engl J Med 319: 525-532
57. Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549
58. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R, Leung SY (2002) Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal Neoplasia. Cancer Res 62: 6451-6455 (Pubitemid 35364105)